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Abstract
Congenital myasthenic syndrome (CMS) refers to a heterogeneous 
group of inherited disorders, characterized by defective transmission 
at the neuromuscular junction (NMJ). Patients with CMS showed 
similar muscle weakness, while other clinical manifestations are 
mostly dependent on genetic factors. This disease, caused by different 
DNA mutations, is genetically inherited. It is also associated with 
mutations of genes at NMJ, involving the acetylcholine receptor 
(AChR) subunits. Here, we present the case of a five-year-old Iranian 
boy with CMS, undergoing targeted sequencing of a panel of genes, 
associated with arthrogryposis and CMS. The patient had six affected 
relatives in his genetic pedigree chart. The investigations indicated 
a homozygous single base pair deletion at exon 12 of the CHRNE 
gene (chr17:4802186delC). This region was conserved across 
mammalian evolution and was not submitted to the 1000 Genomes 
Project database. Overall, the CHRNE variant may be classified as a 
significant variant in the etiology of CMS. It can be suggested that the 
Iranian CMS population carry regional pathogenic mutations, which 
can be detected via targeted and whole genome sequencing. 
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Congenital myasthenic syndrome (CMS) refers to a heterogeneous group 
of inherited genetic disorders, affecting neuromuscular transmission. 
Although most symptoms of CMS appear within several days after 
birth or in early childhood, in rare cases, its onset may be delayed until 
childhood (1). CMS affects not only the muscles moving the eyes, but 
also chewing and swallowing muscles, involved in abnormal physical 
exhaustion (2). CMS is also commonly associated with dysfunctional 
acetylcholine receptor (AChR) ε-subunits. Evidence shows that 
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CHRNE gene mutations lead to AChR deficiency 
(3). The encoded AChR protein can be found in 
the cellular membrane of skeletal muscles at the 
neuromuscular junction (NMJ) (4). The sites, 
products, and disorders of CMS-related genes are 
presented in Table 1. 
The severity of CMS is highly variable, ranging 
from minor symptoms to progressive disabling 
weakness. Although the prevalence of this syndrome 
is unknown, it has been classified as a rare disease 
(6). The diagnosis of CMS is established, based on 
clinical findings, electromyography, genetic tests, 
and measurement of serum AChR antibodies. All 
treatment protocols involve acetylcholinesterase 
inhibitors (9). Targeted sequencing represents a 
cost-effective approach to detect the variants in 
multiple or large genes. 
In the present case report, we aimed to examine 
nucleotide variations in a panel of genes in an 
Iranian male CMS patient. 
Case Presentation
The patient was a five-year-old boy with at least 
six CMS-affected relatives in his family pedigree 
(Figure 1). His parents were second cousins. 
According to the neurology report, he was 
diagnosed with ptosis at birth with diurnal variation 
and a high-arched palate. The muscle biopsy with 
hematoxylin and eosin (H&E) staining revealed a 
striated muscle tissue with significant variations in 
fiber size. The atrophic fibers were rounded and/or 
angular and dispersed. The ATPase reaction at pH 
of 9.4, 4.6, and 4.35 revealed prominent atrophy 
of type II fibers. Also, measurement of blood cells 
showed a higher white cell count (16.5 units) than 
the normal range (4-10). 
After collecting a blood sample, DNA was 
extracted by a manual method. The gene panel 
included the following genes: MYH7, CHAT, 
CHRNA1, CHRNB1, CHRND, CHRNE, CHRNG, 
DPAGT1, GFPT1, LAMB2, MUSK, MYH3, 
MYH8, RAPSN, SCN4A, TNNI2, TNNT3, 
COLQ, DOK7, AGRN, MYBPC1, TPM2, PLEC, 
SLC35A3, ECEL1, GLE1, VIPAS39, VPS33B, 
PIEZO2, UBA1, CHST14, and FBN2. Generally, 
targeted gene sequencing involves targeted capture 
and sequencing of protein-coding regions of 
genomes/genes. Mutations that are identified in 
the exonic regions are generally considered to be 
more pathogenic than variations that occur in non-
coding regions. 
The libraries were sequenced to a mean coverage 
of >80-100X on an Illumina sequencing platform. 
The obtained sequences were aligned to the human 
reference genome (GRCh37/hg19) in the BWA 
software package (10, 11). They were also analyzed 
using the Picard and GATK-Lite toolkit (12, 13) 
to identify variants in targeted genes, associated 
with clinical presentations. Clinically relevant 
mutations were annotated, using the variants 
published in the literature, as well as a set of variant 
databases, including ClinVar (http://www.ncbi.
nlm.nih.gov/clinvar/), OMIM, GWAS, HGMD, 
and SwissVar (http://swissvar.expasy.org/). Only 
non-synonymous and splice-site variants, found 
in the arthrogryposis and CMS panel genes, were 
used for clinical interpretations. 
The results showed a homozygous single base 
pair deletion at exon 12 of the CHRNE gene 
(chr17:4802186delC), causing the frameshift and 
premature truncation of 64 amino acid proteins 
downstream of codon 443 (p.Glu443LysfsTer64; 
ENST00000293780). No other variants were 
detected that need to be reported.
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17p13.2 at the short (p) 
arm of chromosome 
17 at position 13.2
1% AChR epsilon subunit
1- Multiple pterygium syndrome 
lethal type (MUPSL)
2- Slow-channel congenital 
myasthenic syndrome (SCCMS)
3- Fast-channel congenital 
myasthenic syndrome (FCCMS)
CHRND
 2q37.1 at the long (q) 
arm of chromosome 






10q11.23 at the long 
(q) arm of chromosome 






9q31.3 at the long (q) 
arm of chromosome 







1p21.3 at the short (p) 
arm of chromosome 







at the short (p) arm 
of chromosome 










 1q32.1 at the long (q) 
arm of chromosome 
1 at position 32.1
Calcium sensor 1
1- CMS
2- Presynaptic CMS with or without 
motor neuropathy 
COLQ
3p25.1 at the short (p) 
arm of chromosome 
3 at position 25.1
10-15% Acetylcholinesterase
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DOK7
4p16.3 at the short (p) 
arm of chromosome 
4 at position 16.3
10-15%
Connection between 




11p11.2 at the short (p) 
arm of chromosome 
11 at position 11.2
1%  AChR CMS
CHRNB1
17p13.1 at the short (p) 
arm of chromosome 
17 at position 13.1
1%  AChR beta subunit SCCMS
AGRN 
1p36.33 at the short (p) 
arm of chromosome 
1 at position 36.33
1%
1- Laminin G
2- Kazal-type serine 
protease inhibitor




17q23.3 at the long (q) 
arm of chromosome 
17 at position 23.3
1% Sodium channel alpha subunit
B3GLCT
13q12.3 at the long (q) 
arm of chromosome 
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Table 2. Arthrogryposis multiplex congenita
Genes Sites Products Disorders
ECEL1
2q37.1 at the long (q) 
arm of chromosome 2 at 
position 37.1
Endopeptidases (M13) 
and zinc-containing type 
II integral-membrane 
proteins
1- Arthrogryposis multiplex 
congenita
2- Autosomal recessive 
distal arthrogryposis (type 5D) 
TPM2
9p13.3 at the short (p) 
arm of chromosome 9 at 
position 13.3
 β-tropomyosin (part of 
tropomyosin)
1- Cap myopathy
2- Congenital fiber-type 
disproportion
3- Distal arthrogryposis type 1
4- Nemaline myopathy
5- Sheldon-Hall syndrome
6- Arthrogryposis multiplex 
congenita
MYBPC1
12q23.2 at the long (q) 
arm of chromosome 12 at 
position 23.2
Myosin-binding protein C
(a slow skeletal muscle 
isoform)
1- Arthrogryposis multiplex 
congenita
ADCY6
12q13.12 at the long (q) 
arm of chromosome 12 at 
position 13.12
Adenylyl cyclase
1- Arthrogryposis multiplex 
congenita
KRT17
17q21.2 at the long (q) 
arm of chromosome 17 at 
position 21.2
Keratin 17 (K17)
1- Arthrogryposis multiplex 
congenita
KRT16
17q21.2 at the long (q) 
arm of chromosome 17 at 
position 21.2
Keratin 16 (K16)




4p15.2 at the short (p) 
arm of chromosome 4 at 
position 15.2
 RBP-J
1- Arthrogryposis multiplex 
congenita
VIPAS39
14q24.3 at the long (q) 
arm of chromosome 14 at 
position 24.3
Sorting of lysosomal 
proteins
1- Arthrogryposis multiplex 
congenita 
2- Renal dysfunction
3- Cholestasis type 2
NR0B1
Xp21.2 at the short 
(p) arm of the X 
chromosome at position 
21.2
DAX1
1- Arthrogryposis multiplex 
congenita
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Discussion
The muscle AChR contains five subunits of four 
different types (two alpha, one beta, one gamma, 
and one delta). Mutations in the AChR ε-subunit 
are more frequent than mutations of alpha, beta, 
and delta subunits. Mutations in these subunits 
are frequently related to a severe phenotype. The 
TINF2
14q12 at the long (q) arm 




1- Arthrogryposis multiplex 
congenita
CLCN1
7q34 at the long (q) arm 
of chromosome 7 at 
position 34
Chloride channels
1- Arthrogryposis multiplex 
congenita
RBPJ 
4p15.2 at the short (p) 
arm of chromosome 4 at 
position 15.2
RBP-J
(part of the Notch 
signaling pathway)




the long (q) arm 
of chromosome 




1- Arthrogryposis multiplex 
congenita
Figure 1. The patient’s pedigree chart
CHRND gene mutations should be considered 
in severe and early cases of the disease. They 
clinically resemble rapsyn phenotypes with 
recurrent episodic apneas (16). In this regard, 
Hoffmann et al. and Morgan et al. showed that 
mutations in the CHRNG gene resulted in Escobar 
syndrome (EVMPS; 265000), as well as lethal 
multiple pterygium syndrome (LMPS; 253290). 
93
A case report of congenital myasthenic syndrome caused by a mutation in the CHRNE gene in the Iranian population
Iran J Child Neurol. Autumn  2020 Vol. 14 No. 4
The CHRNG gene encodes the AChR gamma 
subunit and is expressed before week 33 of 
pregnancy in humans, but is replaced by the 
ε-subunit (100725) in the perinatal period. 
Therefore, the gamma subunit not only contributes 
to neuromuscular signal transduction, but is also 
important for neuromuscular organogenesis. 
Mutations in the CHRNA gene may cause disorders, 
such as LMPS and CMS (slow- and fast-channel 
CMS). Also, mutations in the CHRNB gene may 
lead to slow-channel CMS. Homozygous or 
compound heterozygous mutations in the CHRNE 
gene (OMIM entry #100725) have been implicated 
in CMS4C, associated with AChR deficiency and 
fast-channel CMS4B (OMIM entry #616324). This 
CHRNE variant has been previously identified 
in five CMS patients with AChR deficiency in 
Southeast of Iran (Khuzestan) (14, 15). It has 
not been submitted to the 1000 Genome Project 
database and is conserved across mammals.
Based on the abovementioned findings, 
this CHRNE variant can be classified as a 
pathogenically significant variant that may be 
included in genetic screenings. Sequencing of this 
variant in the parents (an in vitro strategy) and other 
affected and non-affected members of the family is 
recommended to confirm its significance. It seems 
that mutations in CHRNE genes are common in 
the Iranian population, which may contribute to 
the pathogenicity of CMS. Such variants may be 
detected via further targeted and whole genome 
sequencing. 
In Conclussion
Based on the above mentioned findings, 
this CHRNE variantcan be classified as a 
pathogenically significant variant that maybe 
included ingeneticscreenings. Sequencing of this 
variant in theparents(an in vitrostrategy) and other 
affected and non-affected members of the family is 
recommended to confirm its significance.It seems 
that mutations inCHRNEgenes are common in 
the Iranian population,which may contribute to 
thepathogenicity of CMS. Such variants maybe 
detected via further targeted and wholegenome 
sequencing. 
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